A carregar...
Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
PURPOSE: In the multinational, randomized, double-blind, Phase 3 B2305 study of patients with Cushing’s disease (CD; ClinicalTrials.gov identifier NCT00434148), pasireotide substantially decreased urinary-free cortisol (UFC) levels, decreased mean corticotroph tumor volume, and improved clinical sig...
Na minha lista:
| Publicado no: | Pituitary |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7181422/ https://ncbi.nlm.nih.gov/pubmed/31875276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-019-01021-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|